We are live on ! Find out more
ATRA icon

Atara Biotherapeutics
ATRA

37 hedge funds and large institutions have $27M invested in Atara Biotherapeutics in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

94% more capital invested

Capital invested by funds: $13.9M → $27M (+$13.1M)

16% more funds holding

Funds holding: 32 → 37 (+5)

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

3.44% less ownership

Funds ownership: 30.25% → 26.81% (-3.4%)

Holders
37
Holders Change
+5
Holders Change %
+15.63%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
8
Reduced
7
Closed
4
Calls
$3K
Puts
–
Net Calls
+$3K
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
+$845K
2
Mackenzie Financial
Mackenzie Financial
Ontario, Canada
+$475K
3
Jane Street
Jane Street
New York
+$254K
4
Morgan Stanley
Morgan Stanley
New York
+$242K
5
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
+$197K

Top Sellers

Rank Fund Capital Flow
1
VPC
Vestal Point Capital
New York
-$726K
2
SCA
STALEY CAPITAL ADVISERS
Pennsylvania
-$288K
3
Citadel Advisors
Citadel Advisors
Florida
-$178K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$101K
5
Raymond James Financial
Raymond James Financial
Florida
-$31K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jones Financial Companies
26
Jones Financial Companies
Missouri
$9.66K – – –
TRCT
27
Tower Research Capital (TRC)
New York
$4.9K +$3.94K +342 New
Wells Fargo
28
Wells Fargo
California
$3.6K -$8.05K -700 -74%
JP Morgan Chase
29
JP Morgan Chase
New York
$3.1K – – –
BT
30
Banque Transatlantique
France
$2.52K – – –
RhumbLine Advisers
31
RhumbLine Advisers
Massachusetts
$2.51K – – –
Group One Trading
32
Group One Trading
Illinois
$2.12K – – –
BNP Paribas Financial Markets
33
BNP Paribas Financial Markets
France
$716 – – –
KFP
34
Kerr Financial Planning
California
$322 +$276 +24 New
AIP
35
Alexis Investment Partners
Texas
$215 +$173 +15 New
Osaic Holdings
36
Osaic Holdings
Arizona
$138 – – –
Rockefeller Capital Management
37
Rockefeller Capital Management
New York
$115 +$92 +8 New
VPC
38
Vestal Point Capital
New York
– -$726K -94,085 Closed
Citadel Advisors
39
Citadel Advisors
Florida
– -$178K -23,003 Closed
Raymond James Financial
40
Raymond James Financial
Florida
– -$31K -4,021 Closed
RBI
41
Raiffeisen Bank International
Austria
– -$2.3K -200 Closed
1
2

ATRA Hedge Fund Activity: Q3 2025 in Review

37 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q3 2025, worth a combined $27M — up 94% from $13.9M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new ATRA positions and 4 closed out — a net gain of 5 holders — while 8 added to existing stakes and 7 trimmed.

The largest buyer was Marshall Wace, adding an estimated $845K. The largest seller was Vestal Point Capital, exiting entirely with an estimated $726K sold.

  • 37 institutional investors held Atara Biotherapeutics (ATRA) as of Q3 2025, up from 32 in Q2 2025.
  • Funds reported $27M of Atara Biotherapeutics stock for Q3 2025, up 94% quarter-over-quarter.
  • 9 funds opened new Atara Biotherapeutics positions in Q3 2025 and 4 closed out, a net change of +5 holders.
  • The largest Atara Biotherapeutics buyer in Q3 2025 was Marshall Wace, an estimated $845K added.
  • The largest Atara Biotherapeutics seller in Q3 2025 was Vestal Point Capital, an estimated $726K sold.

Based on aggregated 13F filings for Q3 2025.